Trimethoprim-sulfamethoxazole desensitization in AIDS

Klin Wochenschr. 1988 Apr 15;66(8):351-3. doi: 10.1007/BF01735793.

Abstract

Trimethoprim-sulfamethoxazole (TMS) desensitization was carried out in three patients with AIDS and Pneumocystis carinii pneumonia (PCP) in whom treatment with TMS had to be discontinued after 8 to 12 days due to an allergic reaction. Although the pneumonia was under control we decided for a desensitization to TMS because of the frequent reinfection and the high mortality rate particularly if treatment is incomplete. On the first day the patients took 0.4 mg/2 mg trimethoprim/sulfamethoxazole orally. The dose was increased during 9 successive days to 80 mg/400 mg trimethoprim/sulfamethoxazole. From the 10th to the 16th day 160 mg/800 mg trimethoprim/sulfamethoxazole was given daily and subsequently twice daily which is the recommended dose for prophylaxis of PCP. The desensitization was successful in two patients and a PCP prophylaxis was possible.

MeSH terms

  • Acquired Immunodeficiency Syndrome / complications*
  • Adult
  • Desensitization, Immunologic / methods*
  • Drug Hypersensitivity / prevention & control*
  • Humans
  • Male
  • Pneumonia, Pneumocystis / drug therapy*
  • Pneumonia, Pneumocystis / etiology
  • Sulfamethoxazole / adverse effects*
  • Sulfamethoxazole / therapeutic use
  • Trimethoprim / adverse effects*
  • Trimethoprim / therapeutic use

Substances

  • Trimethoprim
  • Sulfamethoxazole